GlassScriptPhysician profile
Terry Mccaskill
NPI 1720071301
$652.16
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $61.52 · 2021: $27.77 · 2022: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $267.39 | 2019-2022 | |
| Intuitive Surgical, INC. | $166.85 | 2019 | |
| Astellas Pharma US INC | $37.00 | 2022 | |
| Therapeuticsmd, INC. | $34.74 | 2022 | |
| Coloplast Corp | $31.04 | 2022 | |
| Urovant Sciences INC | $27.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.37 | 2022 | |
| Scynexis, INC. | $20.19 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.51 | 2020 | |
| Daiichi Sankyo INC. | $15.91 | 2021 | |
| Mayne Pharma Commercial LLC | $15.16 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Mccaskill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.